About this trial
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.
Eligibility criteria
Qualifiers
Adults aged 18-60
Recently prescribed a GLP-1RA (within one week of prescription)
Fluent in English
Willing to complete the study protocol
Disqualifiers
Children and adults > 60 years of age
Those not taking a GLP-1RA
Those who have been on a GLP-1RA longer than one week
Not fluent in English
Trial design
Treatments tested in this trial
- Hydration Plus
- Control
Treatment groups
Sponsors and collaborators
State University of New York at Buffalo
Lead sponsor
National Institutes of Health (NIH)
Collaborator